دورية
Use Of Pegfilgrastim Primary Prophylaxis By Chemotherapy Cycle Among Patients With Non-Hodgkin's Lymphoma Or Breast Cancer
| العنوان: | Use Of Pegfilgrastim Primary Prophylaxis By Chemotherapy Cycle Among Patients With Non-Hodgkin's Lymphoma Or Breast Cancer |
|---|---|
| المؤلفون: | Langeberg, Wendy J, Siozon, Conchitina C, Morrow, PK, Page, John H, Chia, Victoria M |
| المصدر: | Blood; November 2013, Vol. 122 Issue: 21 p5598-5598, 1p |
| مستخلص: | A recent open-label, randomized, phase III study in patients with breast cancer (BC) treated with myelosuppressive chemotherapy found a 3-fold higher incidence of febrile neutropenia (FN) among patients who received pegfilgrastim (peg) prophylaxis during the first two chemotherapy cycles only compared with those who received peg prophylaxis during all chemotherapy cycles (36% vs 10%, respectively; Aarts et al. Journal of Clinical Oncology, April 29, 2013). We examined the use of peg prophylaxis in a real-world setting to assess if practice conforms to clinical guidelines, which recommend granulocyte colony-stimulating factor (G-CSF) every chemotherapy cycle where the risk of FN is ≥20%. |
| قاعدة البيانات: | Supplemental Index |
| تدمد: | 00064971 15280020 |
|---|---|
| DOI: | 10.1182/blood.V122.21.5598.5598 |